$PHIO SEC Filings

Filed On	Filing
13 Oct 2026	8-K: Other Events Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027
30 Sep 2026	Form 4: Plott Ronald Todd, Director Bought 5,000 shares ($5.15K) · Bought 5,000 shares ($5.2K)
29 Sep 2026	Form 4: Bitterman Robert J, Director Received 400,000 shares as a grant or award
29 Sep 2026	Form 4: Plott Ronald Todd, Director Received 17,000 shares as a grant or award
29 Sep 2026	Form 4: Carson Lisa Cabott, Chief Financial Officer Received 108,000 shares as a grant or award
28 Sep 2026	FORM S-8
28 Sep 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Submission of Matters to a Vote of Security Holders WHEREAS, Phio Pharmaceuticals Corp. (the “Company”) maintains the Phio Pharmaceuticals Corp. 2020 Long-Term Incentive Plan, amended and restated on September 11, 2025 (the “Plan”);
25 Sep 2026	Form 4: Bradford Patricia A, Director Bought 6,500 shares ($6.58K)
23 Sep 2026	Form 4: Bitterman Robert J, Director Bought 2,000 shares ($2.06K)
16 Sep 2026	Form 4: Bradford Patricia A, Director Bought 12,000 shares ($12.4K)
15 Sep 2026	Form 4: Bitterman Robert J, Director Gave up 68,550 shares to cover exercise price or tax ($70.6K)
15 Sep 2026	Form 4: Carson Lisa Cabott, Chief Financial Officer Gave up 12,888 shares to cover exercise price or tax ($13.3K)
14 Sep 2026	8-K: Other Events Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
20 Aug 2026	Form 4: Plott Ronald Todd, Director Bought 15,000 shares ($17.1K)
19 Aug 2026	Form 4: Bitterman Robert J, Director Bought 10,000 shares ($10.6K)
14 Aug 2026	ANNUAL REPORT
14 Aug 2026	ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS
14 Aug 2026	Proxy statement: annual meeting on September 28, 2026 CEO pay $1.2M, up 200%
06 Aug 2026	FORM 10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition

Comments